Full text is available at the source.
Abstract
Colorectal cancer (CRC) has a high mortality rate associated with genetic diversity and treatment resistance.
- TP53 mutations are significant molecular alterations linked to CRC.
- These mutations may disrupt genomic stability.
- TP53 is considered a key target for personalized treatment strategies.
- The genetic heterogeneity of CRC contributes to challenges in effective treatment.
Simplified